调节剂治疗囊性纤维化患者：朝着正确的方向前进。
Modulator treatment for people with cystic fibrosis: moving in the right direction.
机构信息
Faculty of Medicine Health and Life Sciences, Queens University of Belfast, Belfast, UK
出版信息
Eur Respir Rev. 2020 Mar 20;29(155). doi: 10.1183/16000617.0051-2020. Print 2020 Mar 31.
Abstract
相似文献
1
Modulator treatment for people with cystic fibrosis: moving in the right direction.调节剂治疗囊性纤维化患者：朝着正确的方向前进。
Eur Respir Rev. 2020 Mar 20;29(155). doi: 10.1183/16000617.0051-2020. Print 2020 Mar 31.
2
Cystic fibrosis transmembrane conductance regulator modulators: Present and future in cystic fibrosis treatment. A review.囊性纤维化跨膜传导调节因子调节剂：囊性纤维化治疗的现状与未来。综述
Arch Argent Pediatr. 2019 Apr 1;117(2):e131-e136. doi: 10.5546/aap.2019.eng.e131.
3
After the Celebrations: Lessons from the New Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy.庆祝之后：囊性纤维化跨膜传导调节因子调节剂治疗新时代的经验教训
Ann Am Thorac Soc. 2019 Feb;16(2):189-190. doi: 10.1513/AnnalsATS.201810-664ED.
4
How do cystic fibrosis transmembrane conductance regulator mutations produce lung disease?囊性纤维化跨膜传导调节因子突变如何导致肺部疾病？
Curr Opin Pulm Med. 1995 Nov;1(6):435-43. doi: 10.1097/00063198-199511000-00002.
5
Ivacaftor for patients with cystic fibrosis.用于囊性纤维化患者的依伐卡托
Expert Rev Respir Med. 2014 Oct;8(5):533-8. doi: 10.1586/17476348.2014.951333. Epub 2014 Aug 22.
6
Novel, mechanism-based therapies for cystic fibrosis.针对囊性纤维化的新型、基于机制的疗法。
Curr Opin Pediatr. 2005 Jun;17(3):385-92. doi: 10.1097/01.mop.0000158846.95469.6f.
7
Structure-function analysis of a double-mutant cystic fibrosis transmembrane conductance regulator protein occurring in disorders related to cystic fibrosis.在与囊性纤维化相关疾病中出现的双突变囊性纤维化跨膜传导调节蛋白的结构-功能分析
FEBS Lett. 1999 Jun 11;452(3):371-4. doi: 10.1016/s0014-5793(99)00647-x.
8
COUNTERPOINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? No.反驳观点：在囊性纤维化跨膜调节蛋白调节剂治疗时代，成人囊性纤维化的治疗目标与儿童现在有所不同吗？没有。
Chest. 2022 Jan;161(1):21-24. doi: 10.1016/j.chest.2021.06.018.
9
Challenges in the use of highly effective modulator treatment for cystic fibrosis.高效调节剂治疗囊性纤维化的应用挑战。
J Cyst Fibros. 2021 May;20(3):381-387. doi: 10.1016/j.jcf.2021.01.007. Epub 2021 Jan 30.
10
Emerging technologies for cystic fibrosis transmembrane conductance regulator restoration in all people with CF.用于所有囊性纤维化跨膜电导调节因子（CFTR）患者 CFTR 修复的新兴技术。
Pediatr Pulmonol. 2021 Feb;56 Suppl 1(Suppl 1):S32-S39. doi: 10.1002/ppul.24965.
引用本文的文献
1
New Tic Disorder in a Child With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor.接受依列卡福妥/替扎卡福妥/依伐卡托治疗的囊性纤维化儿童出现的新型抽动障碍
J Pediatr Pharmacol Ther. 2024;29(1):82-84. doi: 10.5863/1551-6776-29.1.82. Epub 2024 Feb 7.
2
Evaluating the Effect of Kaftrio on Perspectives of Health and Wellbeing in Individuals with Cystic Fibrosis.评估 Kaftrio 对囊性纤维化个体健康和幸福感的影响。
Int J Environ Res Public Health. 2022 May 17;19(10):6114. doi: 10.3390/ijerph19106114.
3
It's not all about inhaled treatment: challenges with oral therapy in paediatric respiratory medicine.并非全是吸入治疗：儿科呼吸医学中口服疗法面临的挑战。
Breathe (Sheff). 2021 Mar;17(1):210005. doi: 10.1183/20734735.0005-2021.
本文引用的文献
1
Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease.CFTR 调节剂治疗对严重肺囊性纤维化患者结局的影响。
Eur Respir Rev. 2020 Mar 20;29(155). doi: 10.1183/16000617.0112-2019. Print 2020 Mar 31.
2
Adult Care in Cystic Fibrosis.囊性纤维化成人护理。
Semin Respir Crit Care Med. 2019 Dec;40(6):857-868. doi: 10.1055/s-0039-3400289. Epub 2019 Dec 30.
3
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV.无论初始 FEV 变化如何，Lumacaftor/Ivacaftor 均可减少患者的肺部恶化。
J Cyst Fibros. 2019 Jan;18(1):94-101. doi: 10.1016/j.jcf.2018.07.011. Epub 2018 Aug 23.
4
Cystic fibrosis.囊性纤维化。
Lancet. 2016 Nov 19;388(10059):2519-2531. doi: 10.1016/S0140-6736(16)00576-6. Epub 2016 Apr 29.
Zotero 插件